In the blood, neutrophils are inactive but are swept along at high speed.

Neutrophils Neutrophils are normally found in the bloodstream and are the most abundant type of phagocyte, constituting 50 to 60 of the total circulating white blood cells.

Patients who have baseline neutrophil counts 1.5 x 109 l.

Phagocytosis of bacteria by human neutrophils takes on average nine minutes.

The second type involves the use of the enzyme myeloperoxidase from neutrophil granules.

They secrete cytokines that act on the bone marrow to stimulate the production of monocytes and neutrophils, and they secrete some of the cytokines that are responsible for the migration of monocytes and neutrophils out of the bloodstream.

During this process, free radicals are produced by neutrophils to remove damaged tissue.

Neutrophils do not return to the blood they turn into pus cells and die.

Here, activated neutrophils release the contents of their toxic granules into the lung environment.

Neutrophils and macrophages are phagocytes that travel throughout the body in pursuit of invading pathogens.

The sGP forms a dimeric protein that interferes with the signaling of neutrophils, another type of white blood cell, which enables the virus to evade the immune system by inhibiting early steps of neutrophil activation.

This release of substances promotes chemotaxis of more neutrophils to the site of infection, and glomerular cells can be damaged further by the adhesion molecules during the migration of neutrophils.

Experiments have shown that a reduction in the number of neutrophils lessens the effects of acute lung injury, but treatment by inhibiting neutrophils is not clinically realistic, as it would leave the host vulnerable to infection.

The third type uses lactoferrins, which are present in neutrophil granules and remove essential iron from bacteria.

During an infection, millions of neutrophils are recruited from the blood, but they die after a few days.

Neutrophils also play a key role in the development of most forms of acute lung injury.

Abraxane should not be administered until neutrophil counts recover to 1.5 x 109 l.

The innate leukocytes include the phagocytes (macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells.

Myeloperoxidase contains a heme pigment, which accounts for the green color of secretions rich in neutrophils, such as pus and infected sputum.

In cyclic neutropenia, there is a reduction in the level of circulating neutrophils in the blood that occurs about every 21 days.

It should also not be used in patients who are breast feeding or who have low levels of neutrophils in the blood before starting treatment.

This is thought to be due to decreased production and a compensatory prolonged lifespan for circulating neutrophils, which increase numbers of nuclear segments with age.

Neutrophils are normally found in the bloodstream and are the most abundant type of phagocyte, normally representing 50 to 60 of the total circulating leukocytes.

Signals from the infection cause the endothelial cells that line the blood vessels to make a protein called selectin, which neutrophils stick to on passing by.

One litre of human blood contains about five billion neutrophils, which are about 10 micrometers in diameter and live for only about five days.

In the liver, damage by neutrophils can contribute to dysfunction and injury in response to the release of endotoxins produced by bacteria, sepsis, trauma, alcoholic hepatitis, ischemia, and hypovolemic shock resulting from acute hemorrhage.

Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to 1.5 x 109 l and platelets recover to 100 x 109 l.

The type of white blood cell predominantly present (see table) indicates whether meningitis is bacterial (usually neutrophil predominant) or viral (usually lymphocyte predominant), although at the beginning of the disease this is not always a reliable indicator.

Neutrophils travel across epithelial cell lined organs to sites of infection, and although this is an important component of fighting infection, the migration itself can result in disease like symptoms.

Patients who experience severe neutropenia (neutrophil count 0.50 x 109 l for a week or longer) or severe sensory neuropathy during Abraxane therapy should have the dose reduced to 220 mg m2 for subsequent courses.

During the acute phase of inflammation, particularly as a result of bacterial infection, neutrophils migrate toward the site of inflammation in a process called chemotaxis, and are usually the first cells to arrive at the scene of infection.

When neutrophils release their granule contents in the kidney, the contents of the granule (reactive oxygen compounds and proteases) degrade the extracellular matrix of host cells and can cause damage to glomerular cells, affecting their ability to filter blood and causing changes in shape.

Do not use Abraxane if you are allergic (hypersensitive) to paclitaxel or any of the other ingredients of Abraxane if you are breast feeding if you have a low white blood cell count (baseline neutrophil counts 1.5 x 109 l your doctor will advise you on this)

The very common side effects (reported in at least 1 out of 10 patients) are Loss of hair Abnormal decrease in the number of neutrophils in the blood Decrease in the number of white blood cells in the blood Deficiency of red blood cells Reduction in the number of lymphocytes in the blood Effect of peripheral nerves (pain, and numbness) Pain in a joint or joints Pain in the muscles Nausea, diarrhoea Vomiting Weakness and tiredness